Neurocrine Biosciences stock: Q3 revenue jumps 41%, outlook raised

Published on 11/05/2026 at 04:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Neurocrine Biosciences stock follows a stronger quarterly update. Management also lifted its full-year INGREZZA sales outlook.

Results strengthen growth outlook

Neurocrine reported record quarterly product sales above one billion dollars across INGREZZA, CRENESSITY and VYKAT XR.
Management scheduled a research and development day for December 15, 2026, with further clinical milestones ahead.
The expanded product portfolio gives investors more than one commercial growth driver to monitor.

NBIX, US64125C1099, Illustration mit AI erstellt.

Neurocrine Biosciences reported a strong third quarter on Monday, November 2, with revenue growth and higher product sales supporting a raised outlook for INGREZZA. The company said quarterly revenue reached 1.123 billion US dollars for the period ended September 30, up 41 percent from the prior-year quarter, according to PR Newswire.

Portfolio drives quarterly growth

INGREZZA net product sales rose to 801 million US dollars, while CRENESSITY contributed 211 million US dollars and VYKAT XR generated 107 million US dollars. Neurocrine said net product sales exceeded one billion dollars for the first time, reflecting contributions from its three commercial medicines.

Adjusted diluted earnings per share increased to 3.29 US dollars from 2.17 US dollars a year earlier. GAAP diluted earnings per share were 1.96 US dollars, compared with 2.04 US dollars in the prior-year quarter. The difference reflects, among other items, acquisition-related costs, amortization and changes in the fair value of equity investments.

Higher guidance, clinical milestones ahead

Neurocrine raised its 2026 INGREZZA net sales guidance to a range of 2.9 billion to 2.925 billion US dollars, from 2.825 billion to 2.875 billion US dollars previously. The company maintained its research and development outlook while lowering its selling, general and administrative expense ranges.

Management also announced a research and development day in New York on December 15, 2026. The company expects clinical milestones for osavampator in major depressive disorder and direclidine in schizophrenia, while new studies are advancing programs in obesity and Alzheimer's disease.

Neurocrine Biosciences stock traded at 145.38 euros on Lang & Schwarz at 11:00 p.m. CET on Wednesday, November 4. Investors can follow the real-time quote of Neurocrine Biosciences stock.

Neurocrine's business focus

Neurocrine Biosciences is a US biopharmaceutical company focused on discovering, developing and commercializing treatments for neurological, psychiatric, endocrine and immunological disorders. Its commercial portfolio includes therapies for tardive dyskinesia, Huntington's disease chorea, classic congenital adrenal hyperplasia and Prader-Willi syndrome, alongside additional products developed with partners. The company is expanding its pipeline through mid- and late-stage clinical programs while building sales support for its growing product portfolio.

The broader market backdrop remains relevant for US healthcare stocks; see current S&P 500 market coverage.

More news and analyses on Neurocrine Biosciences stock.